ArticleFrontiers in cardiovascular medicine2026
Coronary microvascular dysfunction mediates in-hospital adverse outcomes in ST-segment elevation myocardial infarction patients without standard modifiable cardiovascular risk factors.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have demonstrated that patients with ST-segment elevation myocardial infarction (STEMI) without standard modifiable cardiovascular risk factors (SMuRF-less) experience worse in-hospital outcomes than those with standard modifiable cardiovascular risk factors (SMuRFs); however, the role of a critical pathological mechanism coronary microvascular dysfunction (CMVD) in this context remains unclear. Objectives: To investigate whether CMVD mediates the association between SMuRF-less status and in-hospital major adverse cardiovascular events (MACE). Methods: A total of 1,027 STEMI patients undergoing percutaneous coronary intervention (PCI) were enrolled and classified into a SMuRFs group (≥1 SMuRF, Results: The incidence of in-hospital MACE was significantly higher in the SMuRF-less group than in the SMuRFs group (15.3% vs. 7.0%, Conclusion: Elevated post-procedural caIMR, as a quantitative surrogate of CMVD, independently predicted in-hospital MACE and partially mediated the association between SMuRF-less status and adverse in-hospital outcomes in STEMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.